partnership

container1
container2
container3
container4

Improving patient care at scale requires shared expertise, innovation and coordinated action, which is why AstraZeneca believes in partnering with the NHS. Together, we work to address rising demand, the increasing burden of chronic disease and persistent health inequalities by supporting earlier diagnosis, faster access to appropriate evidence-based medicines and more proactive, prevention-focused care.

Through partnership, we can combine data, clinical insight and real-world evidence to reduce unwarranted variation, improve efficiency, and support better outcomes for patients.

Delivering Transformational Change

Improved respiratory care starts with earlier diagnosis and better access to the most effective treatments. For people living with asthma and COPD, that can mean fewer avoidable trips to hospital. But despite progress, there is still variation in care. The Respiratory Transformation Partnership is a unique collaboration funded by the NHS, government and industry and led by health innovation networks which aims to reshape care and improve outcomes at scale.

Find out more

We have an ambition to one day eliminate cancer as a cause of death.

That means zero lives lost too soon, and zero families left behind. For some cancers, we are getting closer to that goal, but for too many, we still remain too far away. And with one in two people expected to be diagnosed with cancer in their lifetime, the critical need is clear.

Find out more

Find out more about the impact of our partnerships

Learn more now

This is a non-promotional asset produced and funded by AstraZeneca with input from NHS partners associated with the case studies enclosed. It is intended to raise awareness of the impact of partnerships and share learnings from successful projects. It is intended for healthcare professionals, policymakers and the general public.

Find out more about our partnerships to transform Respiratory Care in Wales

Learn more now

This is a non-promotional asset produced and funded by AstraZeneca with input from the NHS Health Boards associated with the case studies enclosed and the National Strategic Clinical Network for Respiratory Conditions. It is intended to raise awareness of the burden of respiratory disease and share learnings from successful projects. It is intended for healthcare professionals, policymakers and the general public.